Company news
Shanghai Henlius Biotech, Inc. news in 2025
Shanghai Henlius Biotech, Inc.'s news releases, calls and decks from 2025, newest first.
Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026
December 23, 2025
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
November 20, 2025
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
November 17, 2025
Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine
October 22, 2025
Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
October 9, 2025
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
September 19, 2025
FUTUONING Sets Sail Commercially with First Prescriptions Across China
September 5, 2025
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
September 2, 2025
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
August 25, 2025
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
July 1, 2025
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
April 29, 2025
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
April 17, 2025
Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report
April 16, 2025
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
March 24, 2025
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer
March 19, 2025
FDA Accepts BLA For Shanghai Henlius Biotech's HLX11, A Pertuzumab Biosimilar
February 11, 2025
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
February 6, 2025
Shanghai Henlius Biotech, Inc. - US FDA Accepts Biologics License Application for HLX11, Biosimilar Candidate of Perjeta
February 3, 2025
Decks in 2025
- H1 2025 Earnings Presentation
Earnings · 54 slides · Aug 25, 2025
- Henlius — H1 2025 Earnings Presentation
Earnings · 54 slides · August 2025
- FY2024 Earnings Presentation
Earnings · 47 slides · Mar 24, 2025